Canada Approves First Prescription Melatonin for Sleep Support in Autistic Children

A Regulated Option for Sleep Support

Canada has approved the first prescription melatonin treatment designed for autistic children and adolescents experiencing persistent sleep differences. SLENYTO®, an extended-release melatonin tablet, was authorized by Health Canada for autistic children and those with Smith-Magenis syndrome (SMS) who experience significant sleep initiation and maintenance patterns.

Sleep differences occur in more than 50% of autistic children, compared to about 30% of non-autistic children, according to a 2025 systematic review in Cureus. These patterns may interact with attention styles, emotional regulation, and learning approaches in complex ways that vary by individual.

Sleep differences occur in more than 50% of autistic children, compared to about 30% of non-autistic children, according to a 2025 systematic review in Cureus.

Evidence and Considerations

While melatonin is available over-the-counter in many regions, SLENYTO® represents the first formulation with pediatric-specific dosing and pharmaceutical-grade purity standards. Its prescription status enables medical supervision for dosing, which shows significant individual variability in response according to the same Cureus review of 18 randomized controlled trials involving 1,200 participants.

The Child Mind Institute notes that while short-term use appears generally safe, questions remain about prolonged use during development. Researchers are particularly examining how individual circadian rhythm differences among autistic individuals may influence melatonin response, as discussed in a 2020 PMC study.

Multidimensional Support Approaches

Clinical guidance emphasizes that sleep supports should be tailored to individual needs. A 2025 American Academy of Neurology practice parameter recommends first considering environmental and behavioral supports, such as:

• Adjusting sensory environments
• Implementing visual schedules
• Modifying sleep-wake routines

When these approaches prove insufficient, melatonin may be introduced under clinical guidance. The Simons Sleep Project, detailed in a December 2025 Nature paper, is developing open-source tools to better understand sleep patterns in neurodevelopmental contexts.

SLENYTO® provides a regulated pharmaceutical option while research continues into both melatonin's mechanisms and broader support strategies for autistic individuals with sleep differences.